在轴性脊柱关节炎中,药物停药的性别差异
Rachael Stovall1, Cinthia Blat2, Eric Roberts2
1University of Washington, Seattle, WA.
Arthritis care & research
|December 2, 2025
概括
与男性相比,患有轴性脊椎关节炎 (axSpA) 的女性更有可能停止服用瘤缩因子抑制剂 (TNFi) 和介素-17抑制剂 (IL-17i). 需要进一步的研究来证实Janus激酶抑制剂 (JAKi) 的发现.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 轴性脊柱关节炎 (axSpA) 是一种影响脊柱的慢性炎症性疾病.
- 治疗选择包括瘤缩因子抑制剂 (TNFi),介素-17抑制剂 (IL-17i) 和简氏激酶抑制剂 (JAKi).
- 了解药物坚持和停药的性别差异对于优化患者护理至关重要.
研究的目的:
- 调查 axSpA 患者中药物停用率的性别差异,这些患者开始使用 TNFi,IL-17i 或 JAKi.
- 确定影响这些基于性别的治疗坚持差异的潜在因素.
主要方法:
- 来自风湿病信息系统有效性 (RISE) 注册表 (2003-2025) 的数据分析.
- 在TNFi,IL-17i和JAKi的新用户中,按性别评估药物停用.
- 利用考克斯回归模型和卡普兰-梅尔曲线,调整社会人口统计学和临床因素,并测试了与年龄,种族和区域贫困指数 (ADI) 的相互作用.
主要成果:
- 在7200名axSpA患者中,女性与男性相比,TNFi停止治疗的风险高出24%,IL-17i停止治疗的风险高出25%.
- 在JAKi用户中,没有观察到停止治疗的显著性别差异.
- 65岁以下的女性是TNFi治疗延续的可能性最低的.
结论:
- 与男性相比,患有axSpA的女性更有可能停止TNFi和IL-17i治疗.
- 这项研究表明,对于特定的axSpA药物,治疗坚持度可能存在基于性别的差异.
- 建议进行更长的随访时间的大型研究,以证实JAKi因潜在低功率而停止治疗的发现.
更多相关视频
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
609
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
609
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
167
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
167
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
135
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
135


